Stock comparison
LeMaitre Vascular
Dr. Reddy's Laboratories Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
RDY
Dr. Reddy's Laboratories Limited
Market cap
$11.32B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LMAT | RDY | Winner |
|---|---|---|---|
| Warren Buffett | 77B | 57C | LMAT |
| Benjamin Graham | 89A | 72B | LMAT |
| Philip Fisher | 81C | 61C | LMAT |
| Peter Lynch | 67B | 55C | LMAT |
| Joel Greenblatt | 56D | 46D | LMAT |
| Charlie Munger | 68D | 49D | LMAT |
| Terry Smith | 69D | 45D | LMAT |
Side-by-side metrics
| Metric | LMAT | RDY |
|---|---|---|
| Market cap | $2.23B | $11.32B |
| P/E (TTM) | 37.1x | 26.0x |
| EV/EBIT | 36.6x | 24.0x |
| ROIC (TTM) | 9.43% | 8.07% |
| Gross margin | 72.39% | 52.77% |
| Net margin | 24.35% | 12.76% |
| Revenue CAGR 5y | 12.75% | 13.31% |
| EPS CAGR 5y | 19.04% | 17.36% |
| Debt / Equity | 0.5x | 0.2x |
| Dividend yield | 0.84% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LMAT leads on
- Net margin24.35%vs 12.76%+48%
- Dividend yield0.84%vs 0.6%+28%
- Gross margin72.39%vs 52.77%+27%
- ROIC (TTM)9.43%vs 8.07%+14%
RDY leads on
- Market cap$11.32Bvs $2.23B+80%
- Debt / Equity0.2xvs 0.5x+56%
- EV/EBIT24.0xvs 36.6x+34%
- P/E (TTM)26.0xvs 37.1x+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.